Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

454.97 +6.35 (+1.42%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

Where Will Vertex Pharmaceuticals Be in 1 Year? ↗

Today 16:22 EDT

The biotech's recent dip might be a buying opportunity.

Via The Motley Fool

CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗

March 23, 2026

The gene-editing stock has been in a tailspin of late.

Via The Motley Fool

Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026

March 20, 2026

As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant...

Via Finterra

Topics Intellectual Property

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Merges Strong Fundamentals with Bullish Technical Setup ↗

March 13, 2026

Via Chartmill

Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. ↗

March 10, 2026

Via Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows High Technical and Setup Ratings for Potential Breakout ↗

February 28, 2026

Via Chartmill

Is CRISPR Therapeutics Stock a Buy Now? ↗

March 20, 2026

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Via The Motley Fool

My Top 3 Drug Stocks for March 2026 ↗

March 20, 2026

These companies have impressive track records of navigating the biggest challenges in their industry.

Via The Motley Fool

Topics Intellectual Property

Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals ↗

March 19, 2026

Both have plenty to offer investors, but one has a better outlook.

Via The Motley Fool

Topics Artificial Intelligence

Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks

March 17, 2026

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...

Via StockStory

Topics Artificial Intelligence

1 Momentum Stock to Research Further and 2 We Ignore

March 16, 2026

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

Via StockStory

Is Vertex Pharmaceuticals Heading to $600? ↗

March 15, 2026

A new product approval may be right around the corner.

Via The Motley Fool

This Stock Just Jumped By 8%: Is It Too Late to Buy? ↗

March 13, 2026

The drugmaker is getting its mojo back.

Via The Motley Fool

2 Reasons to Watch VRTX and 1 to Stay Cautious

March 13, 2026

Vertex Pharmaceuticals’s 22.2% return over the past six months has outpaced the S&P 500 by 19.8%, and its stock price has climbed to $480.31 per share. This ...

Via StockStory

Topics Stocks

Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally

March 11, 2026

In a significant milestone for precision medicine, Vertex Pharmaceuticals (NASDAQ:VRTX) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed...

Via MarketMinute

Topics Stocks

Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc

March 11, 2026

Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted...

Via StockStory

Topics Artificial Intelligence

Explore the top gainers and losers within the S&P500 index in today's session. ↗

March 10, 2026

Via Chartmill

Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

March 10, 2026

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 8.3% in the afternoon session after the company announced positive resul...

Via StockStory

Topics Economy

The Great Biotech Divide: Vertex Soars on Multi-Franchise Breakthroughs as Novo Nordisk Stumbles in the Weight-Loss War

March 10, 2026

The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry...

Via MarketMinute

Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy

March 10, 2026

Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER...

Via MarketMinute

Which S&P500 stocks are moving on Tuesday? ↗

March 10, 2026

Via Chartmill

Top S&P500 movers in Tuesday's pre-market session ↗

March 10, 2026

Via Chartmill

Nasdaq, S&P 500 Futures Turn Green On Iran War De-Escalation Signals: Why NVDA, ORCL, JOBY, VRTX, ZVRA Are On Traders' Radar Today ↗

March 10, 2026

Data from Stocktwits indicated that retail sentiment on SPY and QQQ was stabilizing.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease ↗

March 09, 2026

The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal.

Via Stocktwits

Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree ↗

March 08, 2026

The company has performed well over the long run.

Via The Motley Fool

Topics Intellectual Property Retirement

2 Biotech Giants to Buy in 2026 ↗

March 05, 2026

Both of these players are leaders in their fields.

Via The Motley Fool

Topics Intellectual Property

Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗

March 04, 2026

These two biotechs have a lot in common. Their differences are even more pronounced.

Via The Motley Fool

Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗

March 02, 2026

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

Via The Motley Fool

2 Top Healthcare Stocks to Buy in February ↗

February 26, 2026

Patience should pay off with these two healthcare giants.

Via The Motley Fool

Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline ↗

February 26, 2026

One of these is not like the other.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.